154
views
0
recommends
+1 Recommend
2 collections
    4
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Finding melanoma drugs through a probabilistic knowledge graph

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Metastatic cutaneous melanoma is an aggressive skin cancer with some progression-slowing treatments but no known cure. The omics data explosion has created many possible drug candidates; however, filtering criteria remain challenging, and systems biology approaches have become fragmented with many disconnected databases. Using drug, protein and disease interactions, we built an evidence-weighted knowledge graph of integrated interactions. Our knowledge graph-based system, ReDrugS, can be used via an application programming interface or web interface, and has generated 25 high-quality melanoma drug candidates. We show that probabilistic analysis of systems biology graphs increases drug candidate quality compared to non-probabilistic methods. Four of the 25 candidates are novel therapies, three of which have been tested with other cancers. All other candidates have current or completed clinical trials, or have been studied in in vivo or in vitro. This approach can be used to identify candidate therapies for use in research or personalized medicine.

          Related collections

          Most cited references78

          • Record: found
          • Abstract: found
          • Article: not found

          The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease.

          To pursue a systematic approach to the discovery of functional connections among diseases, genetic perturbation, and drug action, we have created the first installment of a reference collection of gene-expression profiles from cultured human cells treated with bioactive small molecules, together with pattern-matching software to mine these data. We demonstrate that this "Connectivity Map" resource can be used to find connections among small molecules sharing a mechanism of action, chemicals and physiological processes, and diseases and drugs. These results indicate the feasibility of the approach and suggest the value of a large-scale community Connectivity Map project.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

            Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation. We conducted a phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation. Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area intravenously every 3 weeks). Coprimary end points were rates of overall and progression-free survival. Secondary end points included the response rate, response duration, and safety. A final analysis was planned after 196 deaths and an interim analysis after 98 deaths. At 6 months, overall survival was 84% (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group. In the interim analysis for overall survival and final analysis for progression-free survival, vemurafenib was associated with a relative reduction of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P<0.001 for both comparisons). After review of the interim analysis by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended. Response rates were 48% for vemurafenib and 5% for dacarbazine. Common adverse events associated with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects. Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation. (Funded by Hoffmann-La Roche; BRIM-3 ClinicalTrials.gov number, NCT01006980.).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              DrugBank: a comprehensive resource for in silico drug discovery and exploration

              DrugBank is a unique bioinformatics/cheminformatics resource that combines detailed drug (i.e. chemical) data with comprehensive drug target (i.e. protein) information. The database contains >4100 drug entries including >800 FDA approved small molecule and biotech drugs as well as >3200 experimental drugs. Additionally, >14 000 protein or drug target sequences are linked to these drug entries. Each DrugCard entry contains >80 data fields with half of the information being devoted to drug/chemical data and the other half devoted to drug target or protein data. Many data fields are hyperlinked to other databases (KEGG, PubChem, ChEBI, PDB, Swiss-Prot and GenBank) and a variety of structure viewing applets. The database is fully searchable supporting extensive text, sequence, chemical structure and relational query searches. Potential applications of DrugBank include in silico drug target discovery, drug design, drug docking or screening, drug metabolism prediction, drug interaction prediction and general pharmaceutical education. DrugBank is available at .
                Bookmark

                Author and article information

                Contributors
                Journal
                PeerJ Comput Sci
                PeerJ Comput Sci
                peerj-cs
                PeerJ Computer Science
                PeerJ Inc. (San Francisco, USA )
                2376-5992
                13 February 2017
                2017
                : 3
                : e106
                Affiliations
                [1 ]Department of Computer Science, Rensselaer Polytechnic Institute , Troy, NY, USA
                [2 ]Stanford Center for Biomedical Informatics Research, Stanford University School of Medicine , Stanford, CA, USA
                [3 ]Department of Chemical & Biological Engineering, Rensselaer Polytechnic Institute , Troy, NY, USA
                [4 ]Center for Biotechnology & Interdisciplinary Studies, Rensselaer Polytechnic Institute , Troy, NY, USA
                Author information
                http://orcid.org/0000-0003-1085-6059
                http://orcid.org/0000-0003-4727-9435
                Article
                cs-106
                10.7717/peerj-cs.106
                10151034
                b0e57492-34a4-4deb-be93-d1e979d11ee1
                © 2017 McCusker et al.

                This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ Computer Science) and either DOI or URL of the article must be cited.

                History
                : 27 April 2016
                : 27 December 2016
                Funding
                The authors received no funding for this work.
                Categories
                Bioinformatics
                Computational Biology
                Data Science
                World Wide Web and Web Science

                melanoma,knowledge graphs,drug repositioning,uncertainty reasoning

                Comments

                Comment on this article